Suchergebnisse - "Felizarta, Franco"

PubPharm (49)

1

Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings : Results from the TANDEM Study

enthalten in: Infectious diseases and therapy | 2024

von Schneider, S. | Blick, G. | Burke, C. | +13

2

Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1) : a multicentre, double-blind, active-controlled, randomised, phase 2b trial

enthalten in: The lancet. Gastroenterology & hepatology | 2023

von Yuen, M. | Asselah, T. | Jacobson, I. | +116

CommentIn: Lancet Gastroenterol Hepatol. 2023 Sep;8(9):772-773. - PMID 37442151

3

Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial

enthalten in: AIDS patient care and STDs | 2023

von Karver, T. | Pascual-Bernaldez, M. | Berni, A. | +13

4

Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2022

von Spinner, C. | Felizarta, F. | Rizzardini, G. | +16

5

Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development : A long-term follow-up study

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2022

von Poordad, F. | Felizarta, F. | Yao, B. | +10

6

Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development : A long‐term follow‐up study

enthalten in: Liver International | 2022

von Poordad, F. | Felizarta, F. | Yao, B. | +10

7

A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2020

von DeJesus, E. | Harward, S. | Jewell, R. | +13

8

Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials

enthalten in: Journal of viral hepatitis | 2020

von Poordad, F. | Castro, R. | Asatryan, A. | +12

9

Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis : The EXPEDITION-8 trial

enthalten in: Journal of hepatology | 2020

von Brown, R. | Buti, M. | Rodrigues, L. | +19

CommentIn: J Hepatol. 2020 Mar;72(3):389-390. - PMID 31703944

10

Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults

enthalten in: The Journal of antimicrobial chemotherapy | 2020

von Letendre, S. | Mills, A. | Hagins, D. | +11

1
2
3
4
5
Nächster »
[5]